Cargando…

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients

Mostrar otras versiones (1)

The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luchsinger, Larry L., Ransegnola, Brett, Jin, Daniel, Muecksch, Frauke, Weisblum, Yiska, Bao, Weili, George, Parakkal Jovvian, Rodriguez, Marilis, Tricoche, Nancy, Schmidt, Fabian, Gao, Chengjie, Jawahar, Shabnam, Pal, Mouli, Schnall, Emily, Zhang, Huan, Strauss, Donna, Yazdanbakhsh, Karina, Hillyer, Christopher D., Bieniasz, Paul D., Hatziioannou, Theodora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302251/ https://www.ncbi.nlm.nih.gov/pubmed/32577675 http://dx.doi.org/10.1101/2020.06.08.20124792

Ejemplares similares

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients
por: Luchsinger, Larry L., et al.
Publicado: (2020)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Plasma neutralization properties of the SARS-CoV-2 Omicron variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection
por: Poston, Daniel, et al.
Publicado: (2020)

Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection
por: Poston, Daniel, et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
por: Gaebler, Christian, et al.
Publicado: (2022)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

VPS29 Exerts Opposing Effects on Endocytic Viral Entry
por: Poston, Daniel, et al.
Publicado: (2022)

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
por: Muecksch, Frauke, et al.
Publicado: (2020)

Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents
por: Muecksch, Frauke, et al.
Publicado: (2020)

Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland
por: McDonald, Lindsay, et al.
Publicado: (2021)

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies
por: Greaney, Allison J., et al.
Publicado: (2021)

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
por: Greaney, Allison J., et al.
Publicado: (2021)

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
por: Schmidt, Fabian, et al.
Publicado: (2020)

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
por: Schmidt, Fabian, et al.
Publicado: (2020)

Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain
por: Yang, Leerang, et al.
Publicado: (2022)

Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain
por: Yang, Leerang, et al.
Publicado: (2023)

SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
por: Zhang, Fengwen, et al.
Publicado: (2023)

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
por: Muecksch, Frauke, et al.
Publicado: (2022)

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity
por: Muecksch, Frauke, et al.
Publicado: (2021)

A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
por: Baisa, Gary, et al.
Publicado: (2021)

“A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.”
por: Baisa, Gary, et al.
Publicado: (2020)

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
por: Barnes, Christopher O., et al.
Publicado: (2020)

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
por: Barnes, Christopher O., et al.
Publicado: (2020)

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
por: Witte, Leander, et al.
Publicado: (2022)

Preliminary evaluations of 3-dimensional human skin models for their ability to facilitate in vitro the long-term development of the debilitating obligatory human parasite Onchocerca volvulus
por: Malkmus, Christoph, et al.
Publicado: (2020)

Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting
por: McCance, Kirsty, et al.
Publicado: (2022)

The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation
por: George, Parakkal Jovvian, et al.
Publicado: (2020)

Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis
por: Jawahar, Shabnam, et al.
Publicado: (2021)

Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans
por: George, Parakkal Jovvian, et al.
Publicado: (2019)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
por: Muecksch, Frauke, et al.
Publicado: (2021)

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
por: Witte, Leander, et al.
Publicado: (2023)

Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
por: Kastenhuber, Edward R, et al.
Publicado: (2022)

The Th1/Tfh-like biased responses elicited by the rASP-1 innate adjuvant are dependent on TRIF and Type I IFN receptor pathways
por: George, Parakkal Jovvian, et al.
Publicado: (2022)

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo
por: Schäfer, Alexandra, et al.
Publicado: (2020)

Vaccine Breakthrough Infections with SARS-CoV-2 Variants
por: Hacisuleyman, Ezgi, et al.
Publicado: (2021)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_49vqmmbg1eel0aghu26m6hieh0